Matches in SemOpenAlex for { <https://semopenalex.org/work/W3004472927> ?p ?o ?g. }
Showing items 1 to 71 of
71
with 100 items per page.
- W3004472927 abstract "7 Background: Epithelial ovarian cancer (OC) is the most lethal gynecologic cancer with ~22,000 women diagnosed annually in the US. The impact of immune checkpoint inhibition (ICI) in the treatment of solid tumors has been significant. However, the response rates for OC are low ranging from 11-15%. It is critical to explore strategies to enhance the efficacy of ICI immunotherapy in OC. Targeting immunosuppressive factors and cells within the tumor microenvironment (TME) represents a feasible approach. The use of IL12 is attractive because induces potent antitumor activity by targeting myeloid cells and lymphocytes. However its clinical application has been hindered by its potential systemic toxicity. Here we explore the use of low dose intraperitoneal IL12 to enhance the antitumor activity of dual ICI in OC. Methods: Mice bearing ID8-VEGF tumors implanted intraperitoneally received either anti-PD1 alone or dual ICI treatment of anti-PD1 plus anti-CTLA4 with or without low dose IL12. Ascites accumulation was used as surrogate for tumor progression and determined by assessing weight increase. Blood and ascites were analyzed by flow cytometry for frequency of PMN-MDSC, M-MDSC, and activated T cells. Results: Low dose IL12 alone induced a significant delay in ascites accumulation when compared to untreated controls or mice treated with PD1 monotherapy or dual ICI. Addition of IL12 to dual ICI resulted in significant tumor regression and extended survival benefit compared to dual ICI alone. A synergistic effect of IL12 was not observed when combined with PD1 monotherapy. Antitumor responses associated with a marked decrease in the frequency of M-MDSC in blood and a decrease in both PMN- and M-MDSC in ascites. Decrease in MDSC associated with elevated levels of activated T cells. Conclusions: Low dose IL12 can induce regression of ID8-VEGF tumors. However, durable responses were only observed when IL12 was added to dual ICI. This suggests that IL12 can induce changes in the TME, particularly on MDSC, that can potentiate the antitumor activity of dual ICI. Our findings also suggest a crucial role of CTLA4 blockade perhaps via T reg targeting." @default.
- W3004472927 created "2020-02-14" @default.
- W3004472927 creator A5005282856 @default.
- W3004472927 creator A5044873389 @default.
- W3004472927 creator A5075478701 @default.
- W3004472927 creator A5079075086 @default.
- W3004472927 creator A5089239939 @default.
- W3004472927 date "2020-02-10" @default.
- W3004472927 modified "2023-10-18" @default.
- W3004472927 title "Targeting the immunosuppressive tumor microenvironment: Synergistic effect of low-dose IL12 in combination with dual immune checkpoint inhibition in a preclinical model of ovarian cancer." @default.
- W3004472927 doi "https://doi.org/10.1200/jco.2020.38.5_suppl.7" @default.
- W3004472927 hasPublicationYear "2020" @default.
- W3004472927 type Work @default.
- W3004472927 sameAs 3004472927 @default.
- W3004472927 citedByCount "1" @default.
- W3004472927 countsByYear W30044729272021 @default.
- W3004472927 crossrefType "journal-article" @default.
- W3004472927 hasAuthorship W3004472927A5005282856 @default.
- W3004472927 hasAuthorship W3004472927A5044873389 @default.
- W3004472927 hasAuthorship W3004472927A5075478701 @default.
- W3004472927 hasAuthorship W3004472927A5079075086 @default.
- W3004472927 hasAuthorship W3004472927A5089239939 @default.
- W3004472927 hasConcept C121608353 @default.
- W3004472927 hasConcept C126322002 @default.
- W3004472927 hasConcept C149532602 @default.
- W3004472927 hasConcept C154317977 @default.
- W3004472927 hasConcept C202751555 @default.
- W3004472927 hasConcept C203014093 @default.
- W3004472927 hasConcept C2776107976 @default.
- W3004472927 hasConcept C2777701055 @default.
- W3004472927 hasConcept C2780427987 @default.
- W3004472927 hasConcept C2780496750 @default.
- W3004472927 hasConcept C502942594 @default.
- W3004472927 hasConcept C55493867 @default.
- W3004472927 hasConcept C71924100 @default.
- W3004472927 hasConcept C86803240 @default.
- W3004472927 hasConcept C8891405 @default.
- W3004472927 hasConcept C98274493 @default.
- W3004472927 hasConceptScore W3004472927C121608353 @default.
- W3004472927 hasConceptScore W3004472927C126322002 @default.
- W3004472927 hasConceptScore W3004472927C149532602 @default.
- W3004472927 hasConceptScore W3004472927C154317977 @default.
- W3004472927 hasConceptScore W3004472927C202751555 @default.
- W3004472927 hasConceptScore W3004472927C203014093 @default.
- W3004472927 hasConceptScore W3004472927C2776107976 @default.
- W3004472927 hasConceptScore W3004472927C2777701055 @default.
- W3004472927 hasConceptScore W3004472927C2780427987 @default.
- W3004472927 hasConceptScore W3004472927C2780496750 @default.
- W3004472927 hasConceptScore W3004472927C502942594 @default.
- W3004472927 hasConceptScore W3004472927C55493867 @default.
- W3004472927 hasConceptScore W3004472927C71924100 @default.
- W3004472927 hasConceptScore W3004472927C86803240 @default.
- W3004472927 hasConceptScore W3004472927C8891405 @default.
- W3004472927 hasConceptScore W3004472927C98274493 @default.
- W3004472927 hasLocation W30044729271 @default.
- W3004472927 hasOpenAccess W3004472927 @default.
- W3004472927 hasPrimaryLocation W30044729271 @default.
- W3004472927 hasRelatedWork W14024959 @default.
- W3004472927 hasRelatedWork W14151459 @default.
- W3004472927 hasRelatedWork W15627729 @default.
- W3004472927 hasRelatedWork W2855694 @default.
- W3004472927 hasRelatedWork W2880624 @default.
- W3004472927 hasRelatedWork W6320432 @default.
- W3004472927 hasRelatedWork W8036688 @default.
- W3004472927 hasRelatedWork W8724660 @default.
- W3004472927 hasRelatedWork W4714080 @default.
- W3004472927 hasRelatedWork W6893594 @default.
- W3004472927 isParatext "false" @default.
- W3004472927 isRetracted "false" @default.
- W3004472927 magId "3004472927" @default.
- W3004472927 workType "article" @default.